Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
662- EGCG,    Advanced Nanovehicles-Enabled Delivery Systems of Epigallocatechin Gallate for Cancer Therapy
- Review, Var, NA
*BioEnh↑,
661- EGCG,  GoldNP,    Epigallocatechin-3-Gallate-Loaded Gold Nanoparticles: Preparation and Evaluation of Anticancer Efficacy in Ehrlich Tumor-Bearing Mice
- vitro+vivo, NA, NA
Apoptosis↑, TumVol↓,
660- EGCG,  FA,    Epigallocatechin-3-gallate Delivered in Nanoparticles Increases Cytotoxicity in Three Breast Carcinoma Cell Lines
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7 - in-vitro, Nor, MCF10
Apoptosis↑, *toxicity↓, *eff↓,
649- EGCG,  CUR,  PI,    Targeting Cancer Hallmarks with Epigallocatechin Gallate (EGCG): Mechanistic Basis and Therapeutic Targets
- Review, Var, NA
*BioEnh↑, EGFR↓, HER2/EBBR2↓, IGF-1↓, MAPK↓, ERK↓, RAS↓, Raf↓, NF-kB↓, p‑pRB↓, TumCCA↑, Glycolysis↓, Warburg↓, HK2↓, Pyruv↓,
658- EGCG,  MNPs,  MF,    Laminin Receptor-Mediated Nanoparticle Uptake by Tumor Cells: Interplay of Epigallocatechin Gallate and Magnetic Force at Nano-Bio Interface
- in-vitro, GBM, LN229
*BioEnh↑,
657- EGCG,  MNPs,  MF,    Interaction of poly-l-lysine coating and heparan sulfate proteoglycan on magnetic nanoparticle uptake by tumor cells
- in-vitro, GBM, U87MG
*BioEnh↑,
655- EGCG,    A new molecular mechanism underlying the EGCG-mediated autophagic modulation of AFP in HepG2 cells
- in-vitro, HCC, HepG2
AFP↓, TumAuto↑, LC3II↑, TumCG↓, MMP↓,
654- EGCG,  MNPs,  MF,    Characterization of mesenchymal stem cells with augmented internalization of magnetic nanoparticles: The implication of therapeutic potential
- in-vitro, Var, NA
*BioEnh↑,
653- EGCG,    Phase 2 Trial of Daily, Oral Polyphenon E in Patients with Asymptomatic, Rai Stage 0-II Chronic Lymphocytic Leukemia(CLL)
- Trial, CLL, NA
ALC↓, Remission↑,
652- EGCG,  VitK2,  CUR,    Case Report of Unexpectedly Long Survival of Patient With Chronic Lymphocytic Leukemia: Why Integrative Methods Matter
- Case Report, CLL, NA
Remission↑,
651- EGCG,    Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications
ROS↑, p‑AMPK↑, mTOR↓, FAK↓, Smo↓, Gli1↓, HH↓, TumCMig↓, TumCI↓, NOTCH↓, JAK↓, STAT↓, Bcl-2↓, Bcl-xL↓, BAX↑, Casp9↑,
673- EGCG,    Iron Chelation Properties of Green Tea Epigallocatechin-3-Gallate (EGCG) in Colorectal Cancer Cells: Analysis on Tfr/Fth Regulations and Molecular Docking
- in-vitro, CRC, HT-29
IronCh↑, TfR1/CD71↑, FTH1↓,
674- EGCG,    Biocompatible and biodegradable nanoparticles for enhancement of anti-cancer activities of phytochemicals
- Review, Var, NA
*BioEnh↑,
695- EGCG,  TFdiG,    The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention
- in-vitro, NA, HL-60
ROS↑, IronCh↑, Apoptosis↑,
694- EGCG,    Matcha green tea (MGT) inhibits the propagation of cancer stem cells (CSCs), by targeting mitochondrial metabolism, glycolysis and multiple cell signalling pathways
- in-vitro, BC, MCF-7
Glycolysis↓, GAPDH↓, ROS↑, OCR↓, ECAR↓, mTOR↓, OXPHOS↓,
693- EGCG,  CAP,  Phen,    Metabolite modulation of HeLa cell response to ENOX2 inhibitors EGCG and phenoxodiol
- in-vitro, Cerv, HeLa
ENOX2↓, TumCG↓,
692- EGCG,    EGCG: The antioxidant powerhouse in lung cancer management and chemotherapy enhancement
- Review, NA, NA
ROS↑, Apoptosis↑, DNAdam↑, CTR1↑, JWA↑, β-catenin/ZEB1↓, P53↑, Vim↓, VEGF↓, p‑Akt↓, Hif1a↓, COX2↓, ERK↓, NF-kB↓, Akt↓, Bcl-xL↓, miR-210↓,
691- EGCG,    Preclinical Pharmacological Activities of Epigallocatechin-3-gallate in Signaling Pathways: An Update on Cancer
- Review, NA, NA
Apoptosis↑, necrosis↑, TumAuto↑, ERK↓, p38↓, NF-kB↓, VEGF↓,
690- EGCG,    Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer
- in-vitro, Pca, NA
AR↓, miR-21↓, miR-330-5p↑, TumCG↓,
689- EGCG,    EGCG inhibited bladder cancer SW780 cell proliferation and migration both in vitro and in vivo via down regulation of NF-κB and MMP-9
- vitro+vivo, Bladder, SW780
Casp8↑, Casp9↑, Casp3↑, BAX↑, PARP↑, TumVol↓, NF-kB↓, MMP9↓,
688- EGCG,  GEM,    Epigallocatechin-3-Gallate (EGCG) Suppresses Pancreatic Cancer Cell Growth, Invasion, and Migration partly through the Inhibition of Akt Pathway and Epithelial–Mesenchymal Transition: Enhanced Efficacy When Combined with Gemcitabine
- in-vitro, PC, NA
Zeb1↓, β-catenin/ZEB1↓, Vim↓, Akt↓, p‑IGFR↓, TumCG↓, TumCMig↓, TumCI↓,
687- EGCG,    Estrogen receptor-α36 is involved in epigallocatechin-3-gallate induced growth inhibition of ER-negative breast cancer stem/progenitor cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
ER-α36↓,
686- EGCG,    Prevention effect of EGCG in rat's lung cancer induced by benzopyrene
- in-vivo, Lung, NA
NF-kB↓, p50↓, Ki-67↓,
685- EGCG,  CUR,  SFN,  RES,  GEN  The “Big Five” Phytochemicals Targeting Cancer Stem Cells: Curcumin, EGCG, Sulforaphane, Resveratrol and Genistein
- Analysis, NA, NA
Bcl-2↓, survivin↓, XIAP↓, EMT↓, Apoptosis↑, Nanog↓, cMyc↓, OCT4↓, Snail↓, Slug↓, Zeb1↓, TCF↓,
683- EGCG,    Targeting the AMP-Activated Protein Kinase for Cancer Prevention and Therapy
- Review, NA, NA
AMPK↑, TumCP↓, P21↑, mTOR↓, COX2↓,
684- EGCG,    Improving the anti-tumor effect of EGCG in colorectal cancer cells by blocking EGCG-induced YAP activation
- in-vitro, CRC, NA
eff↑, Akt↓, VEGFR2↓, STAT3↓, P53↓, Hippo↓, YAP/TEAD↑,
675- EGCG,    When Natural Compounds Meet Nanotechnology: Nature-Inspired Nanomedicines for Cancer Immunotherapy
- Review, Var, NA
*BioAv↑,
676- EGCG,  Chemo,    The Potential of Epigallocatechin Gallate (EGCG) in Targeting Autophagy for Cancer Treatment: A Narrative Review
- Review, NA, NA
PI3k/Akt/mTOR↓, Apoptosis↑, ROS↑, TumAuto↑,
677- EGCG,    Induction of Endoplasmic Reticulum Stress Pathway by Green Tea Epigallocatechin-3-Gallate (EGCG) in Colorectal Cancer Cells: Activation of PERK/p-eIF2 α /ATF4 and IRE1 α
- in-vitro, CRC, HT-29
ER Stress↑, GRP78/BiP↑, PERK↑, eIF2α↑, ATF4↑, IRE1↑, Apoptosis↑,
678- EGCG,    Cancer Prevention with Green Tea and Its Principal Constituent, EGCG: from Early Investigations to Current Focus on Human Cancer Stem Cells
other↑, TumMeta↓, YMcells↑, CSCs↓,
679- EGCG,  5-FU,    Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer
- in-vitro, CRC, NA
NOTCH1↓, BMI1↓, SUZ12↓, EZH2↓, miR-34a↑, miR-200c↑, miR-145↑, CSCs↓,
680- EGCG,    Cancer preventive and therapeutic effects of EGCG, the major polyphenol in green tea
- Review, NA, NA
NF-kB↓, STAT3↓, PI3K↓, HGF/c-Met↓, Akt↓, ERK↓, MAPK↓, AR↓, Casp↑, Ki-67↓, PARP↑, Bcl-2↓, BAX↑, PCNA↓, p27↑, P21↑,
681- EGCG,    Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models
- vitro+vivo, BC, NA
Casp3↑, Casp8↑, Casp9↑, TumAuto↑, Beclin-1↝, ATG5↝, GlucoseCon↓, lactateProd↓, ATP↝, HK2↓, LDHA↓, Hif1a↓, GLUT1↓, TumVol↓, VEGF↓,
682- EGCG,    Suppressive Effects of EGCG on Cervical Cancer
- Review, NA, NA
E7↓, E6↓, PI3K/Akt↓, P53↑, p27↑, P21↑, CDK2↓, mTOR↓, HIF-1↓, IGF-1↓, EGFR↓, ERK↓, VEGF↓,
3428- EGCG,    Thymoquinone Is a Multitarget Single Epidrug That Inhibits the UHRF1 Protein Complex
- Review, Var, NA
TumCCA↑, UHRF1↓, DNMT1↓, p16↑,
3230- EGCG,    Green Tea Polyphenol Epigallocatechin 3-Gallate, Contributes to the Degradation of DNMT3A and HDAC3 in HCT 116 Human Colon Cancer Cells
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT29
HDAC↓, DNMTs↓,
3229- EGCG,    Epigallocatechin-3-gallate (EGCG) Alters Histone Acetylation and Methylation and Impacts Chromatin Architecture Profile in Human Endothelial Cells
- in-vitro, Nor, HMEC - in-vitro, Nor, HUVECs
HDAC↓,
3228- EGCG,    Targeting fibrotic signaling pathways by EGCG as a therapeutic strategy for uterine fibroids
*cycD1/CCND1↓, *COL1A1↓, *ACTA2↓, *α-SMA↓,
3227- EGCG,    Epigallocatechin-3-gallate treatment to promote neuroprotection and functional recovery after nervous system injury
- NA, Nor, NA
*Rho↓, *IL1↓, *IL6↓, *TNF-α↓,
3226- EGCG,    Epigallocatechin-3-gallate, a green-tea polyphenol, suppresses Rho signaling in TWNT-4 human hepatic stellate cells
- in-vitro, Nor, NA
*Rho↓, other↑,
3225- EGCG,    Epigallocatechin‐3‐Gallate Ameliorates Diabetic Kidney Disease by Inhibiting the TXNIP/NLRP3/IL‐1β Signaling Pathway
- in-vitro, Nor, NA - in-vivo, Nor, NA
*RenoP↑, *NLRP3↓, *TXNIP↓, *ASC↓, *Casp1↓, *IL1β↓, *ROS↓, *TNF-α↓, *IL6↓, *IL18↓,
3224- EGCG,    Epigallocatechin-3-Gallate Prevents Acute Gout by Suppressing NLRP3 Inflammasome Activation and Mitochondrial DNA Synthesis
- in-vitro, Nor, NA
*Casp1↓, *NLRP3↓, *Inflam↓,
3223- EGCG,    The Effects of Green Tea Catechins in Hematological Malignancies
- Review, AML, NA
Prx↓, ROS↑,
3222- EGCG,    Epigallocatechin gallate and mitochondria—A story of life and death
- Review, Nor, NA
*lipid-P↓, *SOD↑, *Catalase↑, GPx↑, *GR↑, *GSTs↑, *GSH↑, *SIRT1↑, *PGC1A↑, *other↑,
3217- EGCG,    Epigallocatechin-3-gallate promotes angiogenesis via up-regulation of Nfr2 signaling pathway in a mouse model of ischemic stroke
- in-vivo, Stroke, NA
*angioG↑, *neuroG↑, *NRF2↑,
3221- EGCG,    EGCG upregulates phase-2 detoxifying and antioxidant enzymes via the Nrf2 signaling pathway in human breast epithelial cells
- in-vitro, Nor, MCF10
*antiOx↑, *GSTA1↑, *NRF2↑,
3220- EGCG,    Dual Roles of Nrf2 in Cancer
- in-vitro, Lung, A549
NRF2↑, eff↓,
3219- EGCG,    Nano-chemotherapeutic efficacy of (−) -epigallocatechin 3-gallate mediating apoptosis in A549 cells: Involvement of reactive oxygen species mediated Nrf2/Keap1signaling
- in-vitro, Lung, A549
ROS↑, RNS↓, MMP↓, NRF2↑, Keap1↓,
3218- EGCG,    Comparative efficacy of epigallocatechin-3-gallate against H2O2-induced ROS in cervical cancer biopsies and HeLa cell lines
- in-vitro, Cerv, HeLa
SOD↑, GPx↑, *antiOx↑, ROS↓,
3241- EGCG,    Epigallocatechin gallate triggers apoptosis by suppressing de novo lipogenesis in colorectal carcinoma cells
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT29 - in-vitro, Liver, HepG2 - in-vitro, Liver, HUH7
tumCV↓, mtDam↑, Apoptosis↑, ATP↓, lipoGen↓, eff↑,

Showing Research Papers: 2751 to 2800 of 6149
Prev Page 56 of 123 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6149

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ENOX2↓, 1,   GPx↑, 2,   Keap1↓, 1,   NRF2↑, 2,   OXPHOS↓, 1,   Prx↓, 1,   RNS↓, 1,   ROS↓, 1,   ROS↑, 7,   SOD↑, 1,  

Metal & Cofactor Biology ⓘ

FTH1↓, 1,   IronCh↑, 2,   TfR1/CD71↑, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,   ATP↝, 1,   MMP↓, 2,   mtDam↑, 1,   OCR↓, 1,   Raf↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   p‑AMPK↑, 1,   cMyc↓, 1,   ECAR↓, 1,   GAPDH↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 2,   HK2↓, 2,   lactateProd↓, 1,   LDHA↓, 1,   lipoGen↓, 1,   PI3K/Akt↓, 1,   PI3k/Akt/mTOR↓, 1,   Pyruv↓, 1,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 4,   p‑Akt↓, 1,   Apoptosis↑, 9,   BAX↑, 3,   Bcl-2↓, 3,   Bcl-xL↓, 2,   Casp↑, 1,   Casp3↑, 2,   Casp8↑, 2,   Casp9↑, 3,   HGF/c-Met↓, 1,   Hippo↓, 1,   JWA↑, 1,   MAPK↓, 2,   necrosis↑, 1,   p27↑, 2,   p38↓, 1,   survivin↓, 1,   YAP/TEAD↑, 1,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 1,  

Transcription & Epigenetics ⓘ

EZH2↓, 1,   miR-145↑, 1,   miR-21↓, 1,   other↑, 2,   p‑pRB↓, 1,   tumCV↓, 1,   YMcells↑, 1,  

Protein Folding & ER Stress ⓘ

eIF2α↑, 1,   ER Stress↑, 1,   GRP78/BiP↑, 1,   IRE1↑, 1,   PERK↑, 1,  

Autophagy & Lysosomes ⓘ

ATG5↝, 1,   Beclin-1↝, 1,   LC3II↑, 1,   TumAuto↑, 4,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   DNMT1↓, 1,   DNMTs↓, 1,   p16↑, 1,   P53↓, 1,   P53↑, 2,   PARP↑, 2,   PCNA↓, 1,   UHRF1↓, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 1,   P21↑, 3,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

BMI1↓, 1,   CSCs↓, 2,   EMT↓, 1,   ERK↓, 5,   Gli1↓, 1,   HDAC↓, 2,   HH↓, 1,   IGF-1↓, 2,   p‑IGFR↓, 1,   miR-330-5p↑, 1,   miR-34a↑, 1,   mTOR↓, 4,   Nanog↓, 1,   NOTCH↓, 1,   NOTCH1↓, 1,   OCT4↓, 1,   PI3K↓, 1,   RAS↓, 1,   Smo↓, 1,   STAT↓, 1,   STAT3↓, 2,   SUZ12↓, 1,   TCF↓, 1,   TumCG↓, 4,  

Migration ⓘ

ER-α36↓, 1,   FAK↓, 1,   Ki-67↓, 2,   miR-200c↑, 1,   MMP9↓, 1,   Slug↓, 1,   Snail↓, 1,   TumCI↓, 2,   TumCMig↓, 2,   TumCP↓, 1,   TumMeta↓, 1,   Vim↓, 2,   Zeb1↓, 2,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature ⓘ

ATF4↑, 1,   EGFR↓, 2,   HIF-1↓, 1,   Hif1a↓, 2,   miR-210↓, 1,   VEGF↓, 4,   VEGFR2↓, 1,  

Barriers & Transport ⓘ

CTR1↑, 1,   GLUT1↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   JAK↓, 1,   NF-kB↓, 6,   p50↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 2,  

Drug Metabolism & Resistance ⓘ

eff↓, 1,   eff↑, 2,  

Clinical Biomarkers ⓘ

AFP↓, 1,   ALC↓, 1,   AR↓, 2,   E6↓, 1,   E7↓, 1,   EGFR↓, 2,   EZH2↓, 1,   HER2/EBBR2↓, 1,   Ki-67↓, 2,   SUZ12↓, 1,  

Functional Outcomes ⓘ

Remission↑, 2,   TumVol↓, 3,  
Total Targets: 149

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   Catalase↑, 1,   GSH↑, 1,   GSTA1↑, 1,   GSTs↑, 1,   lipid-P↓, 1,   NRF2↑, 2,   ROS↓, 1,   SOD↑, 1,  

Core Metabolism/Glycolysis ⓘ

PGC1A↑, 1,   SIRT1↑, 1,  

Cell Death ⓘ

Casp1↓, 2,  

Transcription & Epigenetics ⓘ

other↑, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

neuroG↑, 1,  

Migration ⓘ

ACTA2↓, 1,   COL1A1↓, 1,   Rho↓, 2,   TXNIP↓, 1,   α-SMA↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↑, 1,  

Immune & Inflammatory Signaling ⓘ

ASC↓, 1,   IL1↓, 1,   IL18↓, 1,   IL1β↓, 1,   IL6↓, 2,   Inflam↓, 1,   TNF-α↓, 2,  

Protein Aggregation ⓘ

NLRP3↓, 2,  

Hormonal & Nuclear Receptors ⓘ

GR↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   BioEnh↑, 6,   eff↓, 1,  

Clinical Biomarkers ⓘ

IL6↓, 2,  

Functional Outcomes ⓘ

RenoP↑, 1,   toxicity↓, 1,  
Total Targets: 36

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page